Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases.
Spero’s lead product candidate is SPR720, a novel oral therapy for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections.
Spero also has tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), designed to be the first broad-spectrum oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). In September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP.
Additionally, Spero has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is being developed to treat MDR Gram-negative infections in the hospital setting.
Spero Therapeutics is actively pursuing collaborations with partners for scientific expertise and funding support.
Stock information, SEC filings, corporate governance, IR resources and more.
Collaborative. Exciting. Challenging. Stimulating. Committed. Spero Therapeutics was founded in 2013.
Led by an executive team with deep experience and world-class scientific talent, Spero is dedicated to delivering differentiated medicines that help patients suffering from serious and life-threatening infections.